Skip to main content

Ingenito Gary's Form 4 filing

Catalyst Pharmaceuticals, Inc. (CPRX) · filed Jun 23, 2022

Accession no.
0001161697-22-000319
Filed
Jun 23, 2022
Trade date
Jun 21-22, 2022
Filing delay
2 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 4 non-derivative transactions and 2 derivative transactions. Open-market sales total $990.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Ingenito GaryCIK 0001279473Officer (Chief Medical & Reg. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 21, 2022Common stock, par value $0.001 per shareMOption exerciseAcquired+143,848$4.13+$594,092.24165,901Direct
Jun 21, 2022Common stock, par value $0.001 per shareSSaleDisposed−143,848$6.60F1,F2−$949,396.822,053Direct
Jun 22, 2022Common stock, par value $0.001 per shareMOption exerciseAcquired+6,152$4.13+$25,407.7628,205Direct
Jun 22, 2022Common stock, par value $0.001 per shareSSaleDisposed−6,152$6.61F1,F3−$40,664.7222,053Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 21, 2022Common StockMOption exerciseDisposed−143,848$0.00$01,077,819Direct
Jun 22, 2022Common StockMOption exerciseDisposed−6,152$0.00$01,071,667Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F1

Dr. Ingenito sold the shares on the open market for personal reasons and not as a result of any disagreement with the Registrant. Dr. Ingenito remains an officer of the Company.

Referenced by the price of 2 transactions in Table I.

F2

Shares were sold in various lots from $6.55 to $6.68 per share. The listed sale price represents a weighted average price for the shares sold.

Referenced by the price of 1 transaction in Table I.

F3

Shares were sold in various lots from $6.55 to $6.71 per share. The listed sale price represents a weighted average price for the shares sold.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)